6 terminated. 6 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Terminated 6 |
| Phase 1 | 1 | Terminated 1 |
Follow Plasma Cell Myeloma: new trials by email Literature Review of Plasma Cell Myeloma trials Research Report on Plasma Cell Myeloma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Xisomab 3G3 for the Prevention of Catheter-Associated Thrombosis in Patients With Cancer Receiving Chemotherapy Xisomab 3G3 - Lymphoma, Malignant Solid Neoplasm | Phase 2 | Terminated | OHSU Knight Cancer Institute | 9 | 2021-02-25 | 2024-01-24 |
| Daratumumab-Based Therapy for the Treatment of Newly Diagnosed Multiple Myeloma With Kidney Failure Bortezomib, Daratumumab, Dexamethasone - Plasma Cell Myeloma, Renal Failure | Phase 2 | Terminated | Emory University | 17 | 2020-05-07 | 2024-07-01 |
| Enhancing Anti--Tetanus Vaccine Response After Autologous Stem Cell Transplantation Melphalan, Peripheral Blood Stem Cell Transplantation--CD34 HSCT, Peripheral Blood Stem Cell Transplantation--AHSCT - Plasma Cell Myeloma | Phase 2 | Terminated | University of Nebraska | 8 | 2020-01-09 | 2024-03-12 |
| Allogeneic Stem Cell Transplantation for Multiple Myeloma and Myelofibrosis Busulfan, Cyclophosphamide, Fludarabine - Anemia, ASXL1 Gene Mutation | Phase 2 | Terminated | University of Utah | 6 | 2018-03-30 | 2022-05-05 |
| Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer Cyclophosphamide, Fludarabine Phosphate, Laboratory Biomarker Analysis - Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Leukemia in Remission | Phase 2 | Terminated | Roswell Park Cancer Institute | 31 | 2017-12-07 | 2025-07-04 |
| Melphalan and Bortezomib Prior to Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma Melphalan, Bortezomib, Dexamethasone - Plasma Cell Myeloma, Plasmacytosis | Phase 1 / Phase 2 | Terminated | University of Colorado, Denver | 3 | 2009-11-01 | 2015-03-09 |
Multiple Myeloma (6) · Primary Myelofibrosis (2) · Anemia (1) · Anemia, Aplastic (1) · Anemia, Diamond-Blackfan (1) · Anemia, Sickle Cell (1) · Congenital amegakaryocytic thrombocytopenia (1) · Granulomatous Disease, Chronic (1) · Hemoglobinuria, Paroxysmal (1) · Immunologic Deficiency Syndromes (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (1) · Leukemia, Myeloid, Accelerated Phase (1) · Leukemia, Myeloid, Acute (1) · Leukemia, Myeloid, Chronic-Phase (1)
Blood Protein Disorders (6) · Cardiovascular Diseases (6) · Hematologic Diseases (6) · Hemic and Lymphatic Diseases (6) · Hemorrhagic Disorders (6) · Hemostatic Disorders (6) · Immune System Diseases (6) · Immunoproliferative Disorders (6) · Lymphoproliferative Disorders (6) · Neoplasms (6) · Neoplasms by Histologic Type (6) · Neoplasms, Plasma Cell (6) · Paraproteinemias (6) · Vascular Diseases (6) · Blood Platelet Disorders (2)
Bortezomib (2) · Calcium Dobesilate (2) · Cyclophosphamide (2) · Dexamethasone (2) · Melphalan (2) · Peripheral Blood Stem Cell Transplantation (2) · AB023 (1) · Busulfan (1) · Hematopoietic Stem Cell Transplantation (1) · Lenalidomide (1) · Stem Cell Transplantation (1) · Tetanus Toxoid (1) · Thalidomide (1) · Transplantation, Autologous (1) · Whole-Body Irradiation (1)
Emory University (1) · OHSU Knight Cancer Institute (1) · Roswell Park Cancer Institute (1) · University of Colorado, Denver (1) · University of Nebraska (1) · University of Utah (1)
United States (6)
Catherine Lee, MD (1) · Choon-Kee Lee, MD (1) · Christopher D'Angelo, MD (1) · Joseph Shatzel, M.D. (1) · Philip McCarthy, MD (1) · R. Donald Harvey, PharmD (1)
P30CA138292 (1), R01HL151367 (1)